Adaptilens Featured in C&EN: Celebrating Founder-Led Biotech Innovation

As we reflect on 2024, we're proud to spotlight over 130 remarkable achievements from our entrepreneurial community, driving innovation and impact across industries: • Adaptilens is developing an intraocular lens that responds to the eye's natural signal to focus, eliminating the need for eyeglasses or contact lenses. This year, the company raised $17.5 million in funding. • Akouos, a biotech company focused on restoring hearing in deaf children, was featured in The New York Times for helping a child hear for the first time. • IAMBIC is disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. In 2024, IAMBIC completed Techstars NYC, secured $1.25 million in non-dilutive federal and state funding, and expanded the team with seven key hires. Explore more inspiring accomplishments: https://lnkd.in/duWGZ5Kt

Adaptilens was well represented at the Ophthalmology Innovation Source XIV in San Diego where our CEO Liane Clamen spoke on the panel "Future of Anterior Innovation: A Panel of Disruptors and Visionaries." Thank you Anthony Wallace - Bausch + Lomb Surgical for inviting our CEO and facilitating an inspiring discussion.

Adaptilens is excited to share Rowan Walrath's well-researched and insightful article in C&EN showcasing successful founder-led biotech companies like Adaptilens. We appreciate Rowan's recognition of Adaptilens's Founder and CEO Liane Clamen and Rowan's spotlight on champions of the founder-led movement like Chris Garabedian, Gianna Hoffman-Luca, and their team at Xontogeny and Perceptive Advisors, as well as Tony Kulesa and the Pillar VC team.